UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 ORor 15(d) of ~~The~~the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~November 111, 2023

INNOVATION1 BIOTECH INC.

(Exact name of registrant as specified in its charter)

Nevada	000-55852	82-2275255
(State or other jurisdiction	(Commission	(IRS Employer
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
of incorporation)	File Number)	Identification No.)

179 Route 46W, Suite 15 #147 Rockaway, New Jersey		07866
(Address of principal executive offices)		(Zip Code)

179 Rte 46W, Suite 15 #147

~~Registrant’s telephone number~~Rockaway, ~~including~~New ~~area~~Jersey ~~code:~~07866 ~~(929) 459-4966~~

~~N/A~~(Address of principal executive offices) (Zip Code)

~~(Former~~Registrant's ~~name~~telephone ~~or former address~~number, ifincluding ~~changed~~area ~~since~~code: ~~last report.~~(929) 459-4966

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: ~~N/A~~

~~Indicate~~Title ~~by check mark whether the registrant is an emerging growth company as defined in Rule 405~~ of ~~the~~each ~~Securities~~class ~~Act~~Trading ~~of 1933~~ Symbol(~~§230.405 of this chapter~~s) orName ~~Rule 12b-2~~ of ~~the~~each ~~Securities~~exchange ~~Exchange~~on ~~Act~~which ofregistered ~~1934~~none ~~(§240.12b-2~~not ofapplicable ~~this~~not ~~chapter).~~applicable

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by ~~check~~checkmark ~~mark~~ if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On ~~October~~November 111, 2023, Innovation1 Biotech Inc. (the “Company”) issued a $20,000 Demand Promissory Note (the “Note”) to an accredited investor in consideration for $20,000. The Note: (i) bears 10% interest per annum and (ii) matures on the earlier of January 930, 2024, and five days from the date that the noteholder demands repayment.

~~Item~~The 9foregoing description of the terms of the Note and the transaction contemplated thereby do not purport to be complete and are qualified in its entirety by reference to the form of Note, a copy of which is filed as Exhibit 4.011 ~~Financial~~to ~~Statements~~this Current Report on Form 8-K and ~~Exhibits~~is incorporated herein by reference.

Exhibit No.		Exhibit Description
4.1		Form of Demand Promissory Note
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Item 9.01 Financial Statements and Exhibits

2(d) Exhibits.

SIGNATURES

		Incorporated by Reference
					Filed or Furnished
Exhibit #	Exhibit Description	Form	Date	Number	Herewith
4.1	Form of Demand Promissory Note				Filed
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2

	Innovation1 Biotech Inc.
Date: October 16, 2023	By:	/s/ Frederick E. Pierce
	Name:	Frederick E. Pierce
	Title:	Interim Acting Chief Executive Officer
		Principal Executive and Principal Accounting Officer

SIGNATURES

3Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Innovation1 Biotech Inc.

Date: November 7, 2023	By:	/s/ Frederick E. Pierce, II
		Frederick E. Pierce, II Interim Chief Executive Officer

Filing Compare · Innovation1 Biotech Inc.